Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Jan Philipp Bewersdorf; Xiaoli Mi; Bin Lu; Andrew Kuykendall; David Sallman; Manish Patel; Don Stevens; Alexander Philipovskiy; Grerk Sutamtewagul; Lucia Masarova; Gina Keiffer; Amit Verma; Neha Bhagwat; Min Wang; Andrew Moore; Joseph Rager; Diane Heiser; Sunhee Ro; Wan-Jen Hong; Omar Abdel-Wahab; Eytan M. Stein

doi:10.1038/s41375-025-02515-8

Back

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Journal article

Open access

Peer reviewed

Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David Sallman, Manish Patel, Don Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, …

Leukemia, Vol.39(3), pp.765-769

03/2025

DOI: 10.1038/s41375-025-02515-8

PMCID: PMC11879867

PMID: 39856223

Files and links (1)

url

https://doi.org/10.1038/s41375-025-02515-8View

Published (Version of record) Open Access

Abstract

no abstract

Hematology

Internal Medicine

Oncology

38/91

631/67/1059/602

631/67/1990/1673

Cancer Research

Critical Care Medicine

Intensive

Letter

Medicine

Medicine & Public Health

Details

Title: Subtitle: Phase Ib study of PRT543, an oral protein arginine methyltransferase 5 (PRMT5) inhibitor, in patients with advanced splicing factor-mutant myeloid malignancies
Creators: Jan Philipp Bewersdorf - Memorial Sloan Kettering Cancer Center
Xiaoli Mi - Memorial Sloan Kettering Cancer Center
Bin Lu - Memorial Sloan Kettering Cancer Center
Andrew Kuykendall - Moffitt Cancer Center
David Sallman - Moffitt Cancer Center
Manish Patel - Florida Cancer Specialists & Research Institute
Don Stevens - Norton Healthcare
Alexander Philipovskiy - Florida Cancer Specialists & Research Institute
Grerk Sutamtewagul - University of Iowa
Lucia Masarova - The University of Texas MD Anderson Cancer Center
Gina Keiffer - Sidney Kimmel Cancer Center
Amit Verma - Albert Einstein College of Medicine
Neha Bhagwat - Prelude Therapeutics
Min Wang - Prelude Therapeutics
Andrew Moore - Prelude Therapeutics
Joseph Rager - Prelude Therapeutics
Diane Heiser - Prelude Therapeutics
Sunhee Ro - Prelude Therapeutics
Wan-Jen Hong - Prelude Therapeutics
Omar Abdel-Wahab - Memorial Sloan Kettering Cancer Center
Eytan M. Stein - Memorial Sloan Kettering Cancer Center
Resource Type: Journal article
Publication Details: Leukemia, Vol.39(3), pp.765-769
Publisher: Nature Publishing Group UK
DOI: 10.1038/s41375-025-02515-8
PMID: 39856223
PMCID: PMC11879867
ISSN: 0887-6924
eISSN: 1476-5551
Grant note: R01 CA251138, R01 CA242020, and R01 CA283364; P50 CA254838-01 / U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) (https://doi.org/10.13039/100000054) R01 HL128239 / U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI) (https://doi.org/10.13039/100000050) American Society of Hematology (ASH) (https://doi.org/10.13039/100001422) Edward P. Evans Foundation (https://doi.org/10.13039/100008884) American Society of Clinical Oncology (ASCO) (https://doi.org/10.13039/100006293) Damon Runyon Cancer Research Foundation (Cancer Research Fund of the Damon Runyon-Walter Winchell Foundation) (https://doi.org/10.13039/100001021)
Language: English
Date published: 03/2025
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
Record Identifier: 9984798361502771

Metrics

3 Record Views

See more details